Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine (see CONTRAINDICATIONS).



General care is to be taken by the health-care provider for the safe and effective use of this product.

As for any vaccine, adequate treatment provisions, including epinephrine, should be available for immediate use should an anaphylactic or anaphylactoid reaction occur.

As reported with Haemophilus b Polysaccharide Vaccine and another Haemophilus b Conjugate Vaccine, cases of Haemophilus b disease may occur in the week after vaccination, prior to the onset of the protective effects of the vaccines.

The packaging stopper of this product contains natural rubber latex which may cause allergic reactions.

Instructions to Health-care Provider

The health-care provider should determine the current health status and previous vaccination history of the vaccinee.

The health-care provider should question the patient, parent or guardian about reactions to a previous dose of COMVAX (haemophilus b conjugate and hepatitis b vaccine) , PedvaxHIB or other Haemophilus b conjugate vaccines or RECOMBIVAX HB or other hepatitis B vaccines.

Injection of a blood vessel should be avoided.

COMVAX (haemophilus b conjugate and hepatitis b vaccine) should be given with caution in infants with bleeding disorders such as hemophilia or thrombocytopenia, with steps taken to avoid the risk of hematoma following the injection.

If COMVAX (haemophilus b conjugate and hepatitis b vaccine) is used in persons with malignancies or those receiving immunosuppressive therapy or who are otherwise immunocompromised, the expected immune response may not be obtained.

COMVAX (haemophilus b conjugate and hepatitis b vaccine) is not contraindicated in the presence of HIV infection.68

Laboratory Test Interactions

Sensitive tests (e.g., Latex Agglutination Kits) may detect PRP derived from the vaccine in the urine of some vaccinees for at least 30 days following vaccination with lyophilized PedvaxHIB58; in clinical studies with lyophilized PedvaxHIB, such children demonstrated a normal immune response to the vaccine. It is not known whether antigenuria will occur after vaccination with COMVAX (haemophilus b conjugate and hepatitis b vaccine) .

Carcinogenesis, Mutagenesis, Impairment of Fertility

COMVAX (haemophilus b conjugate and hepatitis b vaccine) has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.


Pregnancy Category C: Animal reproduction studies have not been conducted with COMVAX (haemophilus b conjugate and hepatitis b vaccine) . It is also not known whether COMVAX (haemophilus b conjugate and hepatitis b vaccine) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. COMVAX (haemophilus b conjugate and hepatitis b vaccine) is not recommended for use in women of childbearing age.

Pediatric Use

Safety and effectiveness of COMVAX (haemophilus b conjugate and hepatitis b vaccine) in infants below the age of 6 weeks and above the age of 15 months have not been established. However, studies have demonstrated that PedvaxHIB is safe and immunogenic when administered to infants and children up to the age of 71 months and RECOMBIVAX HB is safe and immunogenic in persons of all ages.

COMVAX (haemophilus b conjugate and hepatitis b vaccine) should not be used in infants younger than 6 weeks of age because this will lead to a reduced anti-PRP response and may lead to immune tolerance (impaired ability to respond to subsequent exposure to the PRP antigen).59-61

Infants born to HBsAg-positive mothers should not receive COMVAX (haemophilus b conjugate and hepatitis b vaccine) but instead should receive Hepatitis B Immune Globulin and Hepatitis B Vaccine (Recombinant) at birth and should complete the hepatitis B vaccination series given according to a particular schedule (see manufacturer's circular for Hepatitis B Vaccine [Recombinant]). (See DOSAGE AND ADMINISTRATION.)

Geriatric Use

This vaccine is NOT recommended for use in adult populations.


58. Goep, J.G., et al. Pediatr Infect Dis J 1(1): 2-5, 1992.

59. Keyserling, H.L., et al. Program and Abstracts of the 30th ICAAC, 1990. (Abst. 63).

60. Ward, J.I., et al. Program and Abstracts of the 32nd ICAAC, 1992. (Abst. 984).

61. Lieberman, J.M., et al. Infect Dis, 199 (Abst.1028).

68. Centers for Disease Control. MMWR 42(RR-4): 1-18, April 9, 1993.

Last reviewed on RxList: 3/4/2009
This monograph has been modified to include the generic and brand name in many instances.


Comvax - User Reviews

Comvax User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Comvax sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations